Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Olema Pharmaceuticals Inc (OLMA)
Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 815,436
  • Shares Outstanding, K 55,097
  • Annual Sales, $ 0 K
  • Annual Income, $ -104,790 K
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.46
Trade OLMA with:

Options Overview Details

View History
  • Implied Volatility 87.03% ( -20.74%)
  • Historical Volatility 84.56%
  • IV Percentile 11%
  • IV Rank 27.61%
  • IV High 232.38% on 04/10/23
  • IV Low 31.60% on 03/30/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 910
  • Volume Avg (30-Day) 360
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 2,560
  • Open Int (30-Day) 4,873

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.49
  • Number of Estimates 7
  • High Estimate -0.40
  • Low Estimate -0.65
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +24.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.94 +23.95%
on 02/29/24
16.77 -11.77%
on 02/13/24
-0.45 (-2.95%)
since 02/01/24
3-Month
10.82 +36.78%
on 01/17/24
16.77 -11.77%
on 02/13/24
+0.22 (+1.51%)
since 12/01/23
52-Week
3.00 +393.33%
on 04/06/23
17.79 -16.81%
on 11/08/23
+10.79 (+269.08%)
since 03/01/23

Most Recent Stories

More News
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
PFE : 26.59 (+0.11%)
ARVN : 47.30 (+2.87%)
OLMA : 14.80 (+19.35%)
AZN : 64.60 (+0.69%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
PFE : 26.59 (+0.11%)
ARVN : 47.30 (+2.87%)
OLMA : 14.80 (+19.35%)
AZN : 64.60 (+0.69%)
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical...

OLMA : 14.80 (+19.35%)
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement...

OLMA : 14.80 (+19.35%)
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage...

OLMA : 14.80 (+19.35%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage...

OLMA : 14.80 (+19.35%)
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

NVS : 102.06 (+1.08%)
PFE : 26.59 (+0.11%)
BEAM : 39.84 (+0.89%)
OLMA : 14.80 (+19.35%)
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S....

OLMA : 14.80 (+19.35%)
2 “Strong Buy” Penny Stocks That Could See Huge Long-Term Gains

The first half of 2022 was marked by concerns over inflation, rising interest rates and recession, with the S&P 500 registering its worst half year since 1970. However, not everyone is seeing dark times...

CDAK : 0.0570 (-55.98%)
OLMA : 14.80 (+19.35%)
Olema Pharmaceuticals (OLMA) Gets a Buy Rating from Cowen & Co.

In a report released yesterday, William Maughan from Cowen & Co. reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report), with a price target of $16.00. The company's shares closed...

OLMA : 14.80 (+19.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 18.30
2nd Resistance Point 16.68
1st Resistance Point 15.74
Last Price 14.80
1st Support Level 13.17
2nd Support Level 11.55
3rd Support Level 10.61

See More

52-Week High 17.79
Last Price 14.80
Fibonacci 61.8% 12.14
Fibonacci 50% 10.40
Fibonacci 38.2% 8.65
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar